A recent study published in JAMA compared the effectiveness of two medications, methadone and buprenorphine/naloxone, for treating opioid use disorder, revealing that patients treated with methadone had a lower rate of treatment discontinuation over 24 months.
Research published in BMC Primary Care finds that only 44% of patients with opioid use disorder in primary care settings adhere to their prescribed buprenorphine treatment, with male sex and unexpected positive opioid toxicology results associated with lower adherence.
An experimental long-acting steroid has shown promising results in providing long-lasting pain relief for knee osteoarthritis, with minimal side effects. Eupraxia Pharmaceuticals plans to conduct a larger Phase III trial for this innovative treatment. (Source: The Lancet Rheumatology)
New EULAR criteria classify hand osteoarthritis phenotypes using radiographic features, enabling more targeted clinical trials for specific joint involvement patterns.
Over 22% of rheumatoid arthritis patients experienced persistent severe pain despite improvements in disease activity after 24 weeks of DMARD therapy, highlighting the complex relationship between inflammation and pain in RA.